RecruitingNot ApplicableNCT06183788

Antibody-mediated NMDA Receptor Encephalitis: Symptoms, Biomarkers, and Mechanisms of the Prolonged Recovery Stage

Sponsor

Fundacion Clinic per a la Recerca Biomédica

Enrollment

20 participants

Start Date

Jan 16, 2023

Study Type

INTERVENTIONAL

Conditions

Anti-NMDA Receptor Encephalitis

Summary

The encephalitis mediated by antibodies against the NMDA receptor (NMDARe) predominantly affects young adults and children resulting in severe neurologic and psychiatric deficits. After overcoming the acute stage, patients are left with long-lasting behavioral, cognitive, and psychiatric alterations with important socio-family-economical implications. Here investigators postulate that a better knowledge of this stage will improve treatment decisions and outcome. In Aim 1, the post-acute stage will be clinically characterized, tools to remotely follow cognitive, behavioral and psychiatric deficits will be provided, and the impact of cognitive rehabilitation will be assessed. In Aim 2, biomarkers (autoimmune, inflammatory, neuronal injury) will be identified as signatures of the acute and post-acute stages. In Aim 3, a mouse model of NMDARe will be used to determine the underlying mechanisms and treatment of the postacute stage.

Eligibility

Min Age: 12 Years

Plain Language Summary

Simplified for easier understanding

This study examines the recovery phase after anti-NMDA receptor encephalitis — a serious brain inflammation caused by the immune system mistakenly attacking NMDA receptors (proteins important for brain communication). Recovery can be slow and incomplete; this study looks at symptoms, biomarkers, and mechanisms that affect the prolonged recovery stage, seeking better ways to support patients. **You may be eligible if...** - You are 12 years old or older - You have been diagnosed with anti-NMDA receptor encephalitis - You are in the post-acute stage (have already been discharged from hospital) and it has been 6 months or less since your hospital discharge **You may NOT be eligible if...** - You are unable to give informed consent (or a parent/guardian cannot on your behalf) - You are unable to travel to the study center - You are still in the acute phase of the illness (still hospitalized) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALRemote cognitive rehabilitation program

Remote cognitive rehabilitation program will be performed through an online validated platform (Guttmann NeuroPersonalTrainer: https://gnpt.es/) run by the psychologists team. This is a Sanitary Product with CE certification (Sanitary Product RPS/430/2014; International Patent \[PCT/ES2008/00677\]) and here will be used within its approved indications. The rehabilitation program will increase in difficulty and decrease in frequency during the first year of follow-up (V1-V3).

Locations(1)

Hospital Clínic de Barcelona

Barcelona, Catalonia, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06183788